Stockscreener 앱 받기
9.43
1.62%
0.15
시간 외 거래:
9.43
전일 마감가:
$9.28
열려 있는:
$9.39
하루 거래량:
3.55M
Relative Volume:
0.83
시가총액:
$2.45B
수익:
$6.29B
순이익/손실:
$750.00M
주가수익비율:
3.2743
EPS:
2.88
순현금흐름:
$586.00M
1주 성능:
-0.11%
1개월 성능:
-3.97%
6개월 성능:
-39.12%
1년 성능:
-54.86%
1일 변동 폭
$9.33
$9.64
1주일 범위
$9.15
$9.64
52주 변동 폭
$8.01
$23.10
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
OGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.43 | 2.41B | 6.29B | 750.00M | 586.00M | 2.88 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar - insights.citeline.com
Does Organon's Raised 2025 Guidance Signal a Turning Point for OGN Investors? - simplywall.st
Kahn Brothers' Q2 2025 13F Filing: Alphabet, Comcast, and Organon Highlights - AInvest
Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 - MSN
Roche Sues Organon in First Case Over Biosimilar Copy of Perjeta - Bloomberg Law News
There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings - Yahoo Finance
Organon & Co. (OGN) Stock Price, News & Analysis - MarketBeat
Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool
OGN’s Market Whiplash: -52.64% YTD Decline, -4.30% Plunge in 30 Days - investchronicle.com
Bullish Organon Insiders Loaded Up On US$651.6k Of Stock - 富途牛牛
Organon & Co.'s Q2 2025 Earnings Call: Unraveling Key Contradictions in Capital Allocation, Nexplanon Growth, and Financial Forecasts - AInvest
LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN) - Defense World
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation - The Malaysian Reserve
Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq
5 Must-Read Analyst Questions From Organon’s Q2 Earnings Call - Yahoo Finance
OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter - Yahoo Finance
Organon's Valuation: Discounted Due to Structural Challenges - AInvest
Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - MSN
Natixis Advisors LLC Has $778,000 Holdings in Organon & Co. (NYSE:OGN) - Defense World
Organon & Co. (OGN): Assessing Dividend Sustainability and Valuation Amid Earnings Pressures and Strategic Catalysts - AInvest
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - uk.finance.yahoo.com
Organon & Co. (OGN) Reports Q2 2025 Results - MSN
Organon Q2 Preview: What to expect? - MSN
Organon & Co. (NYSE:OGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Organon & Co. Reports Q2 2025 Earnings, Raises Full-Year Guidance - AInvest
Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Organon & Co. Reports Q2 2025 Financial Results - The Globe and Mail
Organon & Co. Earnings Call: Resilience Amid Challenges - The Globe and Mail
Organon (OGN) Fiscal Q2 Revenue Beats 1% - AOL.com
Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings - MSN
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) (NYSE:OGN) - Seeking Alpha
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Organon & Co. SEC 10-Q Report - TradingView
Organon & Co. (NYSE:OGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN
Organon Reports Results for the Second Quarter Ended June 30, 2025 - BioSpace
ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co.OGN - Discover 361
Organon & Co. shares rise 1.67% premarket after beating Q2 revenue expectations and raising FY guidance. - AInvest
Organon & Co (OGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth By GuruFocus - Investing.com Canada
Organon: Q2 Earnings Snapshot - Norwalk Hour
Organon raises 2025 revenue guidance by $100M amid Vtama ramp and debt reduction focus - MSN
Organon & Co To Go Ex-Dividend On August 15th, 2025 With 0.02 USD Dividend Per Share - 富途牛牛
Organon reports Q2 adjusted EPS $1.00, consensus 94c - TipRanks
Organon raises FY25 revenue view to $6.28B-$6.38B from $6.13B-$6.33B - TipRanks
OGN Shares Plunge: Lawsuit Drives Market Shock - StocksToTrade
Organon & Co. 2025 Q2ResultsEarnings Call Presentation (NYSE:OGN) - Seeking Alpha
Earnings call transcript: Organon Q2 2025 beats EPS expectations, stock volatile - Investing.com
Organon Becomes Oversold - Nasdaq
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Organon & Co. Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
오가논 & Co 주식 (OGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| COX CARRIE SMITH | Director |
May 14 '25 |
Buy |
8.07 |
12,469 |
100,591 |
12,469 |
| Falcione Aaron | Chief Human Resources Officer |
May 07 '25 |
Buy |
8.77 |
5,500 |
48,235 |
62,974 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
May 06 '25 |
Buy |
9.21 |
8,045 |
74,054 |
52,489 |
| Karp Daniel | Executive VP, Corp. Dev. |
May 06 '25 |
Buy |
8.24 |
3,500 |
28,828 |
46,669 |
| WALSH MATTHEW M | Chief Financial Officer |
May 05 '25 |
Buy |
8.82 |
11,400 |
100,548 |
144,484 |
| Ali Kevin | Chief Executive Officer |
May 05 '25 |
Buy |
8.80 |
34,000 |
299,370 |
282,731 |
| Falcione Aaron | Chief Human Resources Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,732 |
0 |
59,237 |
| Karp Daniel | Executive VP, Corp. Dev. |
Mar 31 '25 |
Option Exercise |
0.00 |
34,677 |
0 |
44,515 |
| Stahler Rachel A | Chief Information Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,334 |
0 |
78,994 |
| WALSH MATTHEW M | Chief Financial Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
34,870 |
0 |
136,903 |
1.46%
1.18%
자본화:
|
볼륨(24시간):